Abstract
Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 255-264 |
| Number of pages | 10 |
| Journal | Expert Review of Hematology |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 3 2019 |
Fingerprint
Keywords
- allogeneic transplant
- Autologous transplant
- CAR T cell
- CD30 directed antibody
- checkpoint blockade
- Hodgkin lymphoma
- immunotherapy
- novel agents
- transplant
ASJC Scopus subject areas
- Hematology
Cite this
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. / Dahi, Parastoo B.; Moskowitz, Craig; Giralt, Sergio A.; Lazarus, Hillard M.
In: Expert Review of Hematology, Vol. 12, No. 4, 03.04.2019, p. 255-264.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma
AU - Dahi, Parastoo B.
AU - Moskowitz, Craig
AU - Giralt, Sergio A.
AU - Lazarus, Hillard M.
PY - 2019/4/3
Y1 - 2019/4/3
N2 - Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.
AB - Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.
KW - allogeneic transplant
KW - Autologous transplant
KW - CAR T cell
KW - CD30 directed antibody
KW - checkpoint blockade
KW - Hodgkin lymphoma
KW - immunotherapy
KW - novel agents
KW - transplant
UR - http://www.scopus.com/inward/record.url?scp=85064744956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064744956&partnerID=8YFLogxK
U2 - 10.1080/17474086.2019.1593135
DO - 10.1080/17474086.2019.1593135
M3 - Review article
C2 - 30874456
AN - SCOPUS:85064744956
VL - 12
SP - 255
EP - 264
JO - Expert Review of Hematology
JF - Expert Review of Hematology
SN - 1747-4086
IS - 4
ER -